Ironwood Pharmaceuticals (IRWD) said Monday that data from a phase 3 trial assessing apraglutide in adults with short bowel syndrome with intestinal failure showed a "consistent treatment effect."

The consistent effect was seen "across subgroups: gender, age, body weight, region, race, ethnicity and [short bowel syndrome characteristics] -- including length of remnant bowel," the company said.

The rare disease affects an estimated 18,000 adults in the US, Europe and Japan, Ironwood said.

The company said it's working to file a new drug application to the US Food and Drug Administration and marketing applications to other regulators for apraglutide to treat adults with the disease.

Ironwood shares were rising past 6% in recent trading.

Price: 4.07, Change: +0.11, Percent Change: +2.65